Sirolimus suppresses circulating fibrocytes in idiopathic pulmonary fibrosis in a randomized controlled crossover trial

BACKGROUND: Fibrocytes are BM-derived circulating cells that traffic to the injured lungs and contribute to fibrogenesis. The mTOR inhibitor, sirolimus, inhibits fibrocyte CXCR4 expression, reducing fibrocyte traffic and attenuating lung fibrosis in animal models. We sought to test the hypothesis th...

Descripción completa

Detalles Bibliográficos
Autores principales: Gomez-Manjarres, Diana C., Axell-House, Dierdre B., Patel, Divya C., Odackal, John, Yu, Victor, Burdick, Marie D., Mehrad, Borna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2023
Materias:
Clinical Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243828/
https://www.ncbi.nlm.nih.gov/pubmed/36853800
http://dx.doi.org/10.1172/jci.insight.166901

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243828/
https://www.ncbi.nlm.nih.gov/pubmed/36853800
http://dx.doi.org/10.1172/jci.insight.166901

Ejemplares similares